CANY
PFE icon

Caxton Associates (New York)’s Pfizer PFE Stock Holding History

Caxton Associates (New York)’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-469,400
Closed -$20.2M – 650
2021
Q3 		$20.2M Buy
+469,400
New +$20.8M 2.23% 7

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caxton Associates (New York)'s PFE Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Pfizer (PFE) stake by 21% in Q4 2024, selling an estimated $440K and leaving 60,414 shares worth $1.6M. The position accounts for 0.05% of the portfolio, ranked #131.

Caxton Associates (New York) first reported a position in PFE in Q1 2014 and has held it in 14 quarters since. The position peaked at $151M in Q2 2022. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

  • Caxton Associates (New York) held 60,414 shares of Pfizer worth $1.6M as of Q4 2024.
  • Caxton Associates (New York) sold 16,211 Pfizer shares in Q4 2024, an estimated $440K.
  • Pfizer made up 0.05% of Caxton Associates (New York)'s portfolio in Q4 2024, its #131 holding.
  • Caxton Associates (New York) first reported a position in Pfizer in Q1 2014 and has held it in 14 quarters since.
  • Caxton Associates (New York)'s Pfizer position peaked at $151M in Q2 2022.
  • 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.